Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 110,731 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 110,731 shares of Tango Therapeutics stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $8.87, for a total value of $982,183.97. Following the sale, the insider now directly owns 203,793 shares in the company, valued at $1,807,643.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, June 28th, Mva Investors, Llc sold 29,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $8.57, for a total value of $248,530.00.
• On Thursday, June 6th, Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.24, for a total value of $456,120.00.
• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.61, for a total transaction of $456,600.00.
• On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.43, for a total transaction of $557,250.00.

Tango Therapeutics Stock Performance

Shares of TNGX traded down $0.89 during midday trading on Tuesday, hitting $8.11. 791,896 shares of the stock traded hands, compared to its average volume of 671,885. The business’s 50 day moving average price is $7.86 and its two-hundred day moving average price is $9.27. The firm has a market capitalization of $866.02 million, a PE ratio of -7.17 and a beta of 0.83. Tango Therapeutics, Inc. has a 1-year low of $2.88 and a 1-year high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). Tango Therapeutics had a negative net margin of 299.88% and a negative return on equity of 44.35%. The firm had revenue of $6.47 million for the quarter, compared to analyst estimates of $7.13 million. As a group, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Charles Schwab Investment Management Inc. lifted its stake in shares of Tango Therapeutics by 205.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 367,357 shares of the company’s stock worth $4,136,000 after acquiring an additional 247,234 shares during the period. Invesco Ltd. raised its stake in shares of Tango Therapeutics by 3,247.3% in the 3rd quarter. Invesco Ltd. now owns 774,738 shares of the company’s stock worth $8,724,000 after buying an additional 751,593 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Tango Therapeutics by 57.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 19,421 shares of the company’s stock worth $219,000 after buying an additional 7,077 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Tango Therapeutics by 47.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,754,852 shares of the company’s stock valued at $19,760,000 after buying an additional 564,971 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Tango Therapeutics by 7.2% during the third quarter. Vanguard Group Inc. now owns 2,939,843 shares of the company’s stock worth $33,103,000 after acquiring an additional 197,624 shares during the period. 78.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on TNGX shares. Wedbush cut their price objective on Tango Therapeutics from $18.00 to $11.00 and set an “outperform” rating on the stock in a research note on Thursday, May 23rd. HC Wainwright reduced their price objective on Tango Therapeutics from $16.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, May 28th. Guggenheim upgraded shares of Tango Therapeutics to a “strong-buy” rating in a research note on Tuesday, May 28th. Barclays reduced their price target on shares of Tango Therapeutics from $18.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, May 24th. Finally, Cantor Fitzgerald assumed coverage on shares of Tango Therapeutics in a research report on Thursday, April 4th. They set an “overweight” rating for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Tango Therapeutics has an average rating of “Buy” and an average price target of $14.17.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.